Literature DB >> 27820670

Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.

Ann-Margret Ervin1,2, Harran Mkocha3, Beatriz Munoz1, Kurt Dreger1, Laura Dize4, Charlotte Gaydos4, Thomas C Quinn4,5, Sheila K West1.   

Abstract

PURPOSE: Immigrants and travelers may be sources of re-emergent infection in trachoma-endemic communities close to trachoma elimination. The primary objective of the A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) trial was to determine whether a newcomer and traveler surveillance and treatment program in addition to annual mass drug administration (MDA) would reduce Chlamydia trachomatis infection when compared to MDA alone.
METHODS: ASANTE was a randomized controlled trial in 52 communities in Kongwa, Tanzania. In 26 intervention communities, monitors treated everyone in new households, in-coming children and guardians in existing households, and all persons in households who had traveled between annual MDA events. A total of 26 usual practice communities received MDA only. Surveys of 100 1-9-year-olds from each community were conducted at baseline and every 6 months up to 2 years to assess clinical trachoma and C. trachomatis infection. Data on demographics and environmental factors were also collected.
RESULTS: Mean prevalences of trachomatous inflammation - follicular (TF) and C. trachomatis were equivalent between the two arms (5.2% and 3.7% in intervention, and 4.9% and 3.6% in usual practice communities, respectively). Of 318 children with TF, 36.5% tested positive for C. trachomatis. TF prevalence was higher among households without a bicycle (p = 0.03) and lower with increasing child's age (p < 0.001). Infection prevalence was higher among households >30 minutes from water (p = 0.015). TF and infection prevalence decreased with increasing years of education (p = 0.004 and p = 0.002, respectively).
CONCLUSION: The ASANTE trial will inform guidance on the surveillance and treatment of persons traveling or newly arriving to communities hypo-endemic for trachoma.

Entities:  

Keywords:  Chlamydia trachomatis; Tanzania; community-based; randomized controlled trial; surveillance; trachoma

Mesh:

Substances:

Year:  2016        PMID: 27820670      PMCID: PMC5279916          DOI: 10.1080/09286586.2016.1238947

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  13 in total

1.  Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.

Authors:  Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West
Journal:  Ophthalmic Epidemiol       Date:  2011-02       Impact factor: 1.648

2.  Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.

Authors:  Sheila K West; Beatriz E Munoz; Harran Mkocha; Charlotte Gaydos; Thomas Quinn
Journal:  Ophthalmic Epidemiol       Date:  2015       Impact factor: 1.648

3.  A simple system for the assessment of trachoma and its complications.

Authors:  B Thylefors; C R Dawson; B R Jones; S K West; H R Taylor
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

Review 4.  Trachoma.

Authors:  Hugh R Taylor; Matthew J Burton; Danny Haddad; Sheila West; Heathcote Wright
Journal:  Lancet       Date:  2014-07-17       Impact factor: 79.321

5.  Epidemiology of ocular chlamydial infection in a trachoma-hyperendemic area.

Authors:  S K West; P Rapoza; B Muñoz; S Katala; H R Taylor
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

6.  Mass treatment with single-dose azithromycin for trachoma.

Authors:  Anthony W Solomon; Martin J Holland; Neal D E Alexander; Patrick A Massae; Aura Aguirre; Angels Natividad-Sancho; Sandra Molina; Salesia Safari; John F Shao; Paul Courtright; Rosanna W Peeling; Sheila K West; Robin L Bailey; Allen Foster; David C W Mabey
Journal:  N Engl J Med       Date:  2004-11-04       Impact factor: 91.245

7.  Travel and implications for the elimination of trachoma in ethiopia.

Authors:  Neelima A Shah; Jenafir House; Takele Lakew; Wondu Alemayehu; Colleen Halfpenny; Kevin C Hong; Jeremy D Keenan; Travis C Porco; John P Whitcher; Thomas M Lietman; Bruce D Gaynor
Journal:  Ophthalmic Epidemiol       Date:  2010-03       Impact factor: 1.648

8.  Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.

Authors:  Luis Carlos Cajas-Monson; Harran Mkocha; Beatriz Muñoz; Thomas C Quinn; Charlotte A Gaydos; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

9.  Trachoma prevalence and associated risk factors in the gambia and Tanzania: baseline results of a cluster randomised controlled trial.

Authors:  Emma M Harding-Esch; Tansy Edwards; Harran Mkocha; Beatriz Munoz; Martin J Holland; Sarah E Burr; Ansumana Sillah; Charlotte A Gaydos; Dianne Stare; David C W Mabey; Robin L Bailey; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

Review 10.  The global burden of trachoma: a review.

Authors:  Matthew J Burton; David C W Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-10-27
View more
  8 in total

1.  Trachomatous scarring among children in a formerly hyper-endemic district of Tanzania.

Authors:  Jacob T Cox; Harran Mkocha; Beatriz Munoz; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2017-12-12

2.  Treating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Laura Dize; Charlotte A Gaydos; Bonnie Swenor; Ann-Margret Ervin; Thomas C Quinn
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

3.  Serology, infection, and clinical trachoma as tools in prevalence surveys for re-emergence of trachoma in a formerly hyperendemic district.

Authors:  Michelle Odonkor; Fahd Naufal; Beatriz Munoz; Harran Mkocha; Mabula Kasubi; Meraf Wolle; Sheila West
Journal:  PLoS Negl Trop Dis       Date:  2021-04-16

4.  Risk factors for the progression of trachomatous scarring in a cohort of women in a trachoma low endemic district in Tanzania.

Authors:  Meraf A Wolle; Beatriz E Muñoz; Fahd Naufal; Michael Saheb Kashaf; Harran Mkocha; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2021-11-19

5.  Risk of seroconversion and seroreversion of antibodies to Chlamydia trachomatis pgp3 in a longitudinal cohort of children in a low trachoma prevalence district in Tanzania.

Authors:  Xinyi Chen; Beatriz Munoz; Harran Mkocha; Charlotte A Gaydos; Laura Dize; Thomas C Quinn; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2022-07-13

6.  Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area.

Authors:  Sheila K West; Beatriz Munoz; Hemjot Kaur; Laura Dize; Harran Mkocha; Charlotte A Gaydos; Thomas C Quinn
Journal:  Sci Rep       Date:  2018-02-23       Impact factor: 4.379

7.  Incidence and progression of trachomatous scarring in a cohort of children in a formerly hyper-endemic district of Tanzania.

Authors:  Michael Saheb Kashaf; Beatriz E Muñoz; Harran Mkocha; Meraf A Wolle; Fahd Naufal; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2020-10-05

8.  The effect of Mass Drug Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Charlotte A Gaydos; Thomas C Quinn
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.